Divi's Laboratories
- Market cap
- ₹ 2,38,497 Cr.
- P/E
- 79.8x
- P/B
- 14.51x
- 52-week range
- 5,647.5 – 9,740
- ROE
- 17%
- ROCE
- 22%
- Dividend yield
- 0.3%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Divi's Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)79.8 against a typical 33.2: pricier than most peers (1st = cheapest).184th of 220
- Sales growth+27.8% against a typical +15.6% from a year earlier.62nd of 197
- Profit growth+65.5% against a typical +18.9% from a year earlier.42nd of 160
- Share price, 3 months+22.1% against a typical −2%.28th of 200
- Size₹ 2,38,497 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).2nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE AA+ | Stable | 7 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Sep 2026 | Reaffirmed | CARE AA+ / CARE A1+ → CARE AA+ | — | CARE | ₹ 515 Cr. | |
| 26 Aug 2025 | Reaffirmed | CARE AA+ / CARE A1+ | — | CARE | ₹ 515 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 1 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 23 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 7 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 6 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 17 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Expenses | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 |
| Operating Profit | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 |
| OPM % | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% |
| Other Income | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 |
| Interest | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 |
| Profit before tax | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 |
| Tax % | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% |
| Net Profit | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| EPS in Rs | 13.11 | 13.49 | 20.27 | 16.2 | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 | 33.98 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 11%
- TTM
- 16%
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 13%
- TTM
- 29%
- 10 Years
- 21%
- 5 Years
- 12%
- 3 Years
- 33%
- TTM
- —
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Divi's Laboratories | ₹ 9,558.50 | ₹ 2,38,497 Cr. | 79.8x | 14.5x | 17% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 38.5x | 5.6x | 14.2% | 19.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,338.00 | ₹ 1,08,059 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,129.40 | ₹ 1,12,658 Cr. | 21.2x | 4.3x | 19.7% | 18.5% |
| Lupin | ₹ 1,928.90 | ₹ 88,202 Cr. | 19.2x | 5x | 26.9% | 19.2% |
Management
- Kiran Satchandra Divi
- Chief Executive Officer, Whole-Time Director
- Venkatesa Perumallu Pasumarthy
- Chief Financial Officer
- Manoranjan Jasti
- Chief Information Officer
- Meka Satish Choudhury
- Compliance Officer, Company Secretary
- Murali Krishna Pr Divi
- Managing Director, Executive Director
- Nilima Prasad Divi
- Whole-Time Director - (Commercial)
- Nimmagadda Venkata Ramana
- Executive Director
- Sureddy Devendra Rao
- Whole-Time Director - (Manufacturing)
Prices are delayed and for information only. Nothing on this page is investment advice.